<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00686179</url>
  </required_header>
  <id_info>
    <org_study_id>D3690C00004</org_study_id>
    <secondary_id>EUdract NO 2007-004859-11</secondary_id>
    <nct_id>NCT00686179</nct_id>
  </id_info>
  <brief_title>Investigate the Effect on the QT/QTc Interval of Repeated and Escalating Doses of AZD3480 During 6 Days</brief_title>
  <acronym>TQT</acronym>
  <official_title>A Double-Blind, Randomised, Multicentre, Placebo-Controlled, 4-Ways Crossover Study to Investigate the Effect on the QT/QTc Interval of Repeated and Escalating Doses of AZD3480 During 6 Days, Using Moxifloxacin as a Positive Control, in Healthy Male Volunteers, CYP2D6 Extensive and Poor Metabolisers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects on cardiac repolarisation of
      supratherapeutic doses of AZD3480 compared to placebo in healthy male volunteers, subgrouped
      as extensive metabolisers and poor metabolisers according to CYP2D6 metabolic capacity, using
      moxifloxacin as positive control.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>QTcX interval (supratherapeutic doses in comparison to placebo).Subject-specific correction of QT, QTcF and QTcB (supportive outcome variables).Bazett QTcB=QT*RR-1/2Fridericia QTcF=QT'RR-1/3</measure>
    <time_frame>11 dECG measurements x 4 (4-way crossover)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>QTcX (therapeutic doses in comparison to placebo).PR-, QRS-, RR-intervals</measure>
    <time_frame>11 dECG measurements x 4 (4-way crossover)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration (AUC, Cmax, tmax etc)</measure>
    <time_frame>11 PK-measurements x 4 (4-way crossover)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Registration of AEs, blood pressure, ECG, clinical laboratory tests</measure>
    <time_frame>From enrolment to follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalating doses of AZD3480 during 6 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Repeated doses of AZD3480 during 6 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo during 6 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo during 5 days, active day 6</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD3480</intervention_name>
    <description>Capsule, oral, single dose, 6 days</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>TC-1734-226</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>Capsule(encapsulated), oral, single dose</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLACEBO</intervention_name>
    <description>Capsule, oral, single dose</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participation in a previous study for genotyping for identification to be extensive or
             poor metaboliser (CYP2D6 enzyme)

          -  Physically and mentally healthy male volunteers

        Exclusion Criteria:

          -  History of clinically significant diseases or illness.

          -  Participation in another study the last 3 months

          -  Prescribed or non-prescribed medications from 3 weeks prior to first treatment day
             until follow-up except for paracetamol (max 1.5 g per day.)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans-Göran Hårdemark</last_name>
    <role>Study Director</role>
    <affiliation>Clinical Neuroscience TA AstraZeneca R&amp;D Södertälje, Sweden</affiliation>
  </overall_official>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2008</study_first_submitted>
  <study_first_submitted_qc>May 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2008</study_first_posted>
  <last_update_submitted>September 24, 2008</last_update_submitted>
  <last_update_submitted_qc>September 24, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2008</last_update_posted>
  <responsible_party>
    <name_title>Hans-Göran Hårdemark, MD, PhD, Medical Science Director, AZD3480</name_title>
    <organization>AstraZeneca R&amp;D, Södertälje, Sweden</organization>
  </responsible_party>
  <keyword>TQT</keyword>
  <keyword>ECG</keyword>
  <keyword>QT</keyword>
  <keyword>QTc</keyword>
  <keyword>AZD3480</keyword>
  <keyword>ECG(QTc effects)</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

